Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Moodys
Chinese Patent Office
Chubb
Medtronic
Merck
Citi
McKinsey

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROSPIUM CHLORIDE

« Back to Dashboard

Clinical Trials for Trospium Chloride

Trial ID Title Status Sponsor Phase Summary
NCT00465959 Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Alkermes, Inc. Phase 1/Phase 2 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00465959 Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Endo Pharmaceuticals Phase 1/Phase 2 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00800462 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Ontario Neurotrauma Foundation Phase 4 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00800462 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Toronto Rehabilitation Institute Phase 4 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Completed Allergan Phase 4 This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Trospium Chloride

Condition Name

Condition Name for Trospium Chloride
Intervention Trials
Overactive Bladder 4
Intestinal Obstruction 2
Cognitive Function 1
Neurogenic Detrusor Overactivity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trospium Chloride
Intervention Trials
Urinary Bladder, Overactive 5
Intestinal Obstruction 2
Ureteral Calculi 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trospium Chloride

Trials by Country

Trials by Country for Trospium Chloride
Location Trials
United States 8
Germany 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trospium Chloride
Location Trials
California 3
Utah 1
Arizona 1
South Carolina 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trospium Chloride

Clinical Trial Phase

Clinical Trial Phase for Trospium Chloride
Clinical Trial Phase Trials
Phase 4 6
Phase 1/Phase 2 1
Phase 1 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trospium Chloride
Clinical Trial Phase Trials
Completed 10
Active, not recruiting 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trospium Chloride

Sponsor Name

Sponsor Name for Trospium Chloride
Sponsor Trials
Allergan 5
University Medicine Greifswald 2
University of North Carolina, Chapel Hill 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trospium Chloride
Sponsor Trials
Industry 8
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
McKinsey
US Army
Teva
Accenture
Merck
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.